This Phase-II RCT (n=20) in Spain randomises methadone-maintained patients to fixed ibogaine (6×100 mg) or ascending ibogaine doses (100→600 mg across six administrations) given when opioid withdrawal appears to support methadone detoxification.
Methadone dependence is difficult to detoxify; this phase II randomised trial at Hospital Universitari Sant Joan evaluates whether repeated oral ibogaine administrations facilitate methadone tapering and detoxification.
Participants are randomised to a fixed regimen (six 100 mg doses) or an ascending regimen (100→600 mg over six administrations). Ibogaine is given when clinical opioid withdrawal appears; methadone is interrupted and reduced as specified.
Ibogaine hydrochloride 100 mg per administration, six administrations.
Six administrations of 100 mg each; methadone interrupted; if withdrawal recurs half prior methadone dose given.
Ibogaine hydrochloride ascending doses over six administrations.
Ascending single doses 100→200→300→400→500→600 mg over six administrations; methadone interrupted; if withdrawal recurs half prior methadone dose given.